TY - JOUR
T1 - Antibody recognition of complement factor H reveals a flexible loop involved in atypical hemolytic uremic syndrome pathogenesis
AU - Yokoo, Takanori
AU - Tanabe, Aki
AU - Yoshida, Yoko
AU - Caaveiro, Jose M.M.
AU - Nakakido, Makoto
AU - Ikeda, Yoichiro
AU - Fujimura, Yoshihiro
AU - Matsumoto, Masaneori
AU - Entzminger, Kevin
AU - Maruyama, Toshiaki
AU - Okumura, C. J.
AU - Nangaku, Masaomi
AU - Tsumoto, Kouhei
N1 - Funding Information:
We thank the staff of the Photon factory for excellent technical support. Access to beamline AR-NW12A was granted by the Photon Factory Advisory Committee (Proposal 2020G125). This work was funded in part by Japan Society for the Promotion of Science (grant no. 20K16377 to A. T. 16H02420 and 20H02531 to K. T.) and by Japan Agency for Medical Research and Development (grant no. JP20 AM0101094j to K. T.). The super-computing resources used in this study were provided by the Human Genome Center at the Institute of Medical Science, the University of Tokyo, Japan.
Funding Information:
Funding and additional information—This work was funded in part by Japan Society for the Promotion of Science (grant no. 20K16377 to A. T. 16H02420 and 20H02531 to K. T.) and by Japan Agency for Medical Research and Development (grant no. JP20 AM0101094j to K. T.). The super-computing resources used in this study were provided by the Human Genome Center at the Institute of Medical Science, the University of Tokyo, Japan.
Publisher Copyright:
© 2022 THE AUTHORS.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Atypical hemolytic uremic syndrome (aHUS) is a disease associated with dysregulation of the immune complement system, especially of the alternative pathway (AP). Complement factor H (CFH), consisting of 20 domains called complement control protein (CCP1-20), downregulates the AP as a cofactor for mediating C3 inactivation by complement factor I. However, anomalies related to CFH are known to cause excessive complement activation and cytotoxicity. In aHUS, mutations and the presence of anti-CFH autoantibodies (AAbs) have been reported as plausible causes of CFH dysfunction, and it is known that CFH-related aHUS carries a high probability of end-stage renal disease. Elucidating the detailed functions of CFH at the molecular level will help to understand aHUS pathogenesis. Herein, we used biophysical data to reveal that a heavy-chain antibody fragment, termed VHH4, recognized CFH with high affinity. Hemolytic assays also indicated that VHH4 disrupted the protective function of CFH on sheep erythrocytes. Furthermore, X-ray crystallography revealed that VHH4 recognized the Leu1181–Leu1189CCP20 loop, a known anti-CFH AAbs epitope. We next analyzed the dynamics of the C-terminal region of CFH and showed that the epitopes recognized by anti-CFH AAbs and VHH4 were the most flexible regions in CCP18-20. Finally, we conducted mutation analyses to elucidate the mechanism of VHH4 recognition of CFH and revealed that VHH4 inserts the Trp1183CCP20 residue of CFH into the pocket formed by the complementary determining region 3 loop. These results suggested that anti-CFH AAbs may adopt a similar molecular mechanism to recognize the flexible loop of Leu1181-Leu1189CCP20, leading to aHUS pathogenesis.
AB - Atypical hemolytic uremic syndrome (aHUS) is a disease associated with dysregulation of the immune complement system, especially of the alternative pathway (AP). Complement factor H (CFH), consisting of 20 domains called complement control protein (CCP1-20), downregulates the AP as a cofactor for mediating C3 inactivation by complement factor I. However, anomalies related to CFH are known to cause excessive complement activation and cytotoxicity. In aHUS, mutations and the presence of anti-CFH autoantibodies (AAbs) have been reported as plausible causes of CFH dysfunction, and it is known that CFH-related aHUS carries a high probability of end-stage renal disease. Elucidating the detailed functions of CFH at the molecular level will help to understand aHUS pathogenesis. Herein, we used biophysical data to reveal that a heavy-chain antibody fragment, termed VHH4, recognized CFH with high affinity. Hemolytic assays also indicated that VHH4 disrupted the protective function of CFH on sheep erythrocytes. Furthermore, X-ray crystallography revealed that VHH4 recognized the Leu1181–Leu1189CCP20 loop, a known anti-CFH AAbs epitope. We next analyzed the dynamics of the C-terminal region of CFH and showed that the epitopes recognized by anti-CFH AAbs and VHH4 were the most flexible regions in CCP18-20. Finally, we conducted mutation analyses to elucidate the mechanism of VHH4 recognition of CFH and revealed that VHH4 inserts the Trp1183CCP20 residue of CFH into the pocket formed by the complementary determining region 3 loop. These results suggested that anti-CFH AAbs may adopt a similar molecular mechanism to recognize the flexible loop of Leu1181-Leu1189CCP20, leading to aHUS pathogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85130448632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130448632&partnerID=8YFLogxK
U2 - 10.1016/j.jbc.2022.101962
DO - 10.1016/j.jbc.2022.101962
M3 - Article
C2 - 35452676
AN - SCOPUS:85130448632
SN - 0021-9258
VL - 298
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 6
M1 - 101962
ER -